The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
For the treatment of Superficial Femoral Artery
The company reported lifetime high EBIDTA of Rs. 250 crores
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Subscribe To Our Newsletter & Stay Updated
